Abstract
Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.
Keywords: Clinical trials, Combined targeted therapy, Novel targeted agents, Renal cell carcinoma, Sequential targeted therapy
Current Cancer Drug Targets
Title:Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Volume: 13 Issue: 3
Author(s): Matteo Santoni, Mimma Rizzo, Luciano Burattini, Rossana Berardi, Giacomo Carteni and Stefano Cascinu
Affiliation:
Keywords: Clinical trials, Combined targeted therapy, Novel targeted agents, Renal cell carcinoma, Sequential targeted therapy
Abstract: Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.
Export Options
About this article
Cite this article as:
Santoni Matteo, Rizzo Mimma, Burattini Luciano, Berardi Rossana, Carteni Giacomo and Cascinu Stefano, Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1568009611313030009
DOI https://dx.doi.org/10.2174/1568009611313030009 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Radio-Sensitizing Effect of Pharmacological Concentration of Ascorbic Acid on Human Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets A Review on Metal Nanoparticles from Medicinal Plants: Synthesis, Characterization and Applications
Nanoscience & Nanotechnology-Asia Condition Optimization and Production of Extracellular l-Arginine Deiminase from Vibrio Alginolyticus 1374
Current Biotechnology Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Immunomodulatory Effects of <i>Allium sativum</i> L. and its Constituents against Viral Infections and Metabolic Diseases
Current Topics in Medicinal Chemistry Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology